Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Ovarian Neoplasms 5Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Radiation Pneumonitis 2Peritoneal Neoplasms 2Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophagogastric Adenocarcinoma 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Sunitinib 64Nivolumab 42pembrolizumab 36Bevacizumab 32Everolimus 31Sorafenib 25pazopanib 23Axitinib 23cabozantinib 14aldesleukin 13Ipilimumab 13temsirolimus 11Interferon alpha-2 11Cyclophosphamide 10avelumab 9Magnetic Resonance Spectroscopy 9Interleukin-2 9lenvatinib 8atezolizumab 8Radiosurgery 8Gemcitabine 8Immunoglobulin G 7Erlotinib Hydrochloride 7Disulfides 6fludarabine phosphate 5Radiotherapy 5Fluorodeoxyglucose F18 5peginterferon alfa-2b 4Vorinostat 4Tyrosine Kinase Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Renal Cell × nintedanib × Clear all
NCT01024920 2021-07-19

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

Boehringer Ingelheim

Phase 2 Completed
99 enrolled 45 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡